IL-31, is primarily produced by Th2 cells and directly activates sensory neurons to induce pruritus (itching). By binding to IL-31, riltovetbart blocks its interaction with the IL-31 receptor complex, thereby reducing scratching behavior, skin lesions, and inflammation in canine allergic dermatitis.